Development and Evaluation of Cone-Specific Promoters in Non-human Primates for Gene Therapy of Congenital Cone Diseases Including Achromatopsia
Guo-jie Ye; Ewa Budzynski; Peter Sonnentag; Michael Nork; Nader Sheibani; Sanford L. Boye; William W. Hauswirth; Jeffrey D. Chulay
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. AGTC's lead product candidates, which are each in the preclinical stage, focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are rare diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments.
David Carey Lazar Partners Ltd.T: (212) 867-1768 firstname.lastname@example.org Corporate Contact: Larry BullockChief Financial Officer Applied Genetic Technologies CorporationT: (386) 462-2204 email@example.com